Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905839 | 0.92 | LMNA (0.45) | LMNAPOLBMCOLN3MAPTSMN1; SMN2 | |
| SCHEMBL4905829 | 0.91 | LMNA (0.53) | LMNAMAPTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL4906802 | 0.87 | POLB (0.44) | LMNAPOLBMCOLN3MAPTSMN1; SMN2 | |
| SCHEMBL4906945 | 0.87 | LMNA (0.47) | LMNAMAPTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL4895965 | 0.84 | LMNA (0.53) | LMNAMAPTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL4904702 | 0.82 | LMNA (0.48) | LMNAMAPTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL4895785 | 0.82 | KEAP1 (0.49) | LMNAPOLBMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4906576 | 0.82 | MMP2 (0.45) | LMNAMAPTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL4899728 | 0.81 | LMNA (0.48) | LMNAMAPTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL4906452 | 0.81 | ALDH1A1 (0.41) | LMNAMAPTSMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | LMNA 317/4885POLB 1488/4885MCOLN3 3061/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | LMNA 319/4885POLB 1807/4885MCOLN3 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.